Effects of denosumab treatment and discontinuation on human growth plates. - Wikidata - awgldk - TriplyDB

Effects of denosumab treatment and discontinuation on human growth plates.

Effects of denosumab treatment and discontinuation on human growth plates.

http://www.wikidata.org/entity/Q37616880

about

The management of osteoporosis in children.Denosumab and surgery for the treatment of Perthes' disease in a 9-year-old boy: favorable course documented by comprehensive imaging- a case report.Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.Fibrous dysplasia of bone: craniofacial and dental implications.Pediatric Osteoporosis: Diagnosis and Treatment Considerations.Denosumab for the treatment of giant cell tumor of the bone.Childhood cancer chemotherapy-induced bone damage: pathobiology and protective effects of resveratrol and other nutraceuticals.Monoclonal antibodies for treating osteoporosis.Different clinical presentation and management of temporal bone fibrous dysplasia in children.Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases.Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.

P2860

Q30251490-DA7071C0-3F5B-4066-B784-6FE0E41B48E8 Q33697123-33CB6EB6-7284-4E66-9035-BFBB3675EB83 Q37653297-5C7E800E-7B91-42AB-99B8-CA99514979BC Q38712724-E22D29E6-E197-4EFA-8D23-FC1CF4877A62 Q38834385-8399C6EF-E529-44C8-9A29-EC9C87EAAE82 Q38918970-22E2F716-8331-43C6-B5AA-B9156144C1EA Q38919235-F8551EBD-01C7-420B-9219-064FDE0C7886 Q38921958-12FC09D0-6AC0-4C31-AAF7-39A5967F31DF Q38986160-697D93A2-A20F-4621-AB40-40527D8E4B51 Q39405101-E7B54F99-CE15-433A-BDC6-63202727E2FF Q47638169-486EEB11-709B-479F-BFEF-1061A24D10FD Q48241293-D7D7455E-0BEA-445D-B9EA-798AB6D3317E Q48331949-9DBEB748-7690-4D99-A2ED-2724025CF420 Q50555382-E719E27A-96ED-4A7A-AC1D-60DD38BE1D50

P2860

Effects of denosumab treatment and discontinuation on human growth plates.

http://www.wikidata.org/entity/Q37616880

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of denosumab treatment and discontinuation on human growth plates.

@en

Effects of denosumab treatment and discontinuation on human growth plates.

@nl

type

label

Effects of denosumab treatment and discontinuation on human growth plates.

@en

Effects of denosumab treatment and discontinuation on human growth plates.

@nl

prefLabel

Effects of denosumab treatment and discontinuation on human growth plates.

@en

Effects of denosumab treatment and discontinuation on human growth plates.

@nl

P1433

Q37616880-5B6350BD-A5D2-4DB4-A588-C4C259D867B4

P1476

Q37616880-8D669B2B-99AD-47A7-91C0-C650C10EEC83

P2093

Q37616880-25A196AC-7B60-4582-80B6-32641A3C6A37

Q37616880-467D23A6-1420-41B9-BD37-530EF2F3C1B4

Q37616880-4CD73864-7D04-462F-BEFE-3DD59FD6F216

Q37616880-5B47591A-E610-456B-81D2-90DBEDFF1774

Q37616880-7D57F3B0-895E-4B87-91F1-075FED22C2E7

Q37616880-9B17344C-BDBA-4C74-A395-D555F6F4B9C2

Q37616880-C0E5AA09-A82F-4185-AE0F-1D8605ADDCBC

Q37616880-CD6874C4-893C-4E95-B854-0A199584A011

P2860

Q37616880-05C9114C-42AF-4B4E-BB9F-7A4537CAF644

Q37616880-0767767A-9DCA-45B4-AAB8-EA23DC99CC47

Q37616880-0EC98028-9A98-47D0-A2F0-AD8E2E547858

Q37616880-181575AD-DF53-42EB-9211-B1957E5B0DC8

Q37616880-3E1D8C96-7AC1-414B-81EC-046662E50EBE

Q37616880-4BAFEFA0-2865-4ED2-8580-2801F60F6DD0

Q37616880-4F0225B9-17C3-44E2-A673-1D3ADEE948F5

Q37616880-55C3B251-8B7B-4C0F-963E-FF9EA473C791

Q37616880-87F5D41A-85B0-436B-950D-CF9E9B0A1D51

Q37616880-88E6230E-9313-46DC-AFC4-A57DDC53BB5B

P304

Q37616880-00DB62B3-0ECE-4C85-9DD8-42274DBD0BCC

P31

Q37616880-9CB39286-EAF2-4F45-8E01-344CBD982CBB

P356

Q37616880-1EE90350-6DA4-4529-BEFE-81B794961B2A

P407

Q37616880-EA53D96A-3D70-4A48-AA14-8AC745C12CC9

P433

Q37616880-78BED229-88A4-4363-9ECC-B21353F66788

P478

Q37616880-179DED50-87B0-425E-A840-EC4F0850D2DF

P577

Q37616880-3ADEA21C-70A6-41AB-9987-5AE61328C475

P5875

Q37616880-31F63AD4-B82C-4B7F-A4A7-2DECA0B16883

P698

Q37616880-E3879722-80DD-4E31-8D60-1B00044BF77E

P932

Q37616880-71AA11A1-7513-4111-A856-3998AE588D8D

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Effects of denosumab treatment and discontinuation on human growth plates.

@en

P2093

Alfredo A Molinolo

http://www.w3.org/2001/XMLSchema#string

Alison M Boyce

http://www.w3.org/2001/XMLSchema#string

Frances A Farley

http://www.w3.org/2001/XMLSchema#string

Howard D Wang

http://www.w3.org/2001/XMLSchema#string

Jeffrey Y Tsai

http://www.w3.org/2001/XMLSchema#string

Josephine Z Kasa-Vubu

http://www.w3.org/2001/XMLSchema#string

Michael T Collins

http://www.w3.org/2001/XMLSchema#string

Rachel I Gafni

http://www.w3.org/2001/XMLSchema#string

P2860

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

Denosumab and bisphosphonates: different mechanisms of action and effects.

Denosumab treatment for fibrous dysplasia.

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

P304

891-897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2013-3081

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259723733

http://www.w3.org/2001/XMLSchema#string

P698

24423331

http://www.w3.org/2001/XMLSchema#string

P932

3942242

http://www.w3.org/2001/XMLSchema#string